- ‘Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Koros C*, Stamelou M*, Simitsi A, Beratis I, Papadimitriou D, Papagiannakis N, Fragkiadaki S, Kontaxopoulou D, Papageorgiou SG, Stefanis L. ‘in Neurology. 2018 Mar 6;90(10):e864-e869. (* Equally contributed)
- ‘Genetics of Parkinson;s Disease: Genotype–Phenotype Correlations’ C. Koros, A. Simitsi, L. Stefanis in International Review of Neurobiology, 2017, 132:197-231.
- ‘123I-FP-CIT SPECT imaging in a p.A53T alpha-synuclein Parkinson’s disease cohort versus PD’. Koros, C., Simitsi, A., Prentakis, A., Beratis, I., Papadimitriou, D., Kontaxopoulou, D., Fragkiadaki, S., Papagiannakis, N., Seibyl, J., Marek, K., Papageorgiou, S.G., Geronicola Trapali, X., Stamelou, M , Stefanis, L.in Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451
- ‘Frontotemporal dementia spectrum: first genetic screen in a Greek cohort ’ Ramos EM., Koros C. , Dokuru DR., Van Berlo V., Kroupis C., Wojta K., Wang Q., Andronas N., Matsi S., Beratis I., Huang AY., Lee S., Bonakis A. , Florou-
Hatziyiannidou C. , Fragkiadaki S., Kontaxopoulou D., Papastefanopoulou V.,Stamelou M., Miller BL., Stefanis L., Papatriantafyllou J.,. Papageorgiou SG.,Coppola G. In Neurobiol Aging, 2019 Mar;75:224.e1-224.e8. ‘’Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.’’ Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. in Lancet Neurol. 2019 Jun 19. pii: S1474-4422(19)30140-1 ‘’DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson;s disease: Longitudinal data from the PPMI study.’’ Koros C, Simitsi AM, Prentakis A, Papagiannakis N, Bougea A, Pachi I, Papadimitriou D, Beratis I, Papageorgiou SG, Stamelou M, Trapali XG, Stefanis L. in Parkinsonism Relat Disord. 2020 Jun 22;77:36-42. doi: 10.1016/j.parkreldis.2020.06.019. ‘’A Novel SNCA A30G Mutation Causes Familial Parkinson’s Disease.’ ’Liu H*, Koros C*, Strohäker T, Schulte C, Bozi M, Varvaresos S, Ibáñez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, Maniati M, Papageorgiou SG, Hauser AK, Becker S, Zweckstetter M*, Stefanis L*, Gasser T.* in Mov Disord. 2021 Jul;36(7):1624-1633. (* Equally contributed) ‘’Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.’’ Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Pachi I, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. J Parkinsons Dis. 2020;10(2):481-487. doi: 10.3233/JPD-191860. ‘’Parkinsonism and dementia.’’ Koros C, Stefanis L, Scarmeas N. J Neurol Sci. 2022 Feb 15;433:120015. doi: 10.1016/j.jns.2021.120015. ‘’Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. ‘’Simitsi AM, Koros C, Stamelou M, Beratis I, Efthymiopoulou E, Papadimitriou D, Bougea A, Picillo M, Stanitsa E, Papagiannakis N, Antonelou R, Pachi I, Papageorgiou SG, Barone P, Stefanis L. Parkinsonism Relat Disord. 2022 May;98:72-74. doi: 10.1016/j.parkreldis.2022.04.001. | |